Loading...

Michael Evans, PhD

TitleAssistant Professor
SchoolUCSF School of Medicine
DepartmentRadiology
Address185 Berry St B N
San Francisco CA 94107
Phone415-353-3442
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Saint Mary's College of MarylandBA2001Chemistry
    The Scripps Research InstitutePhD2007Chemistry
    Memorial Sloan Kettering Cancer CenterPostdoctoral2013Human Oncology and Pathogenesis Program
    Collapse Awards and Honors
    American Cancer Society2017  - 2021Research Scholar Award
    American Brain Tumor Association2017  - 2018Discovery Award
    UCSF Academic Senate2016  - 2017Team Science Award
    UCSF2016  - 2017Brain Tumor SPORE Developmental Research Project
    UCSF2016  - 2017Program in Cancer Imaging and Therapy Pilot Award
    DOD Prostate Cancer Research Program2015  - 2017Idea Development Award
    UCSF Academic Senate2014  - 2015Pilot Award
    Prostate Cancer Foundation2013  - 2016David H. Koch Young Investigator Award
    National Cancer Institute2012  - 2017Pathway to Independence Award
    Imaging and Radiation Sciences Brigde Program, MSKCC2012  - 2014Research Grant
    Imaging and Radiation Sciences Bridge Program, Memorial Sloan Kettering Cancer Center2011Research Award
    Brain Tumor Center of Memorial Sloan Kettering Cancer Center2011Research Award
    National Institutes of Health and Memorial Sloan Kettering Cancer Center2007  - 2010R25 Fellowship

    Collapse Overview 
    Collapse Overview
    Michael Evans, PhD, is an Assistant Professor in Residence in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is an experienced chemical biologist with a focus on molecular imaging and organic chemistry. Dr. Evans earned a BA in Chemistry from St. Mary’s College, Maryland and he obtained his PhD in Organic Chemistry from The Scripps Research Institute in La Jolla, California under the supervision of Professor Benjamin Cravatt, followed by postdoctoral fellowship in Molecular Imaging from the Memorial Sloan Kettering Cancer Center in New York under the supervision of Professors Charles Sawyers and Jason Lewis. In October 2013, Dr. Evans accepted the Assistant Professor in Residence position at UCSF.

    Dr. Evans specializes in small molecule synthesis, proteomics, and preclinical development and translation of new radiotracers. By combining his expertise in chemical biology and molecular imaging, Dr. Evans and his group seek to discover and exploit for imaging biomarkers directly regulated by central oncogenes. By approaching molecular imaging as a chemical biologist, Dr. Evans aims to create a repertoire of biomarkers that can be applied to define which oncogenes are active in a given tumor, as well as interpret the extent to which the activity of the oncogene is suppressed by a therapeutic intervention. To date, he has developed biomarkers measuring the activity of the androgen receptor and MYC in prostate cancer, and his group is now actively developing new imaging biomarkers to other important oncogenes.

    Dr. Evans is a member of the American Chemical Society, the American Association for Cancer Research, the Society of Nuclear Medicine and Molecular Imaging, and the World Molecular Imaging Society. He has been invited nationally and internationally to lecture about his research. Dr. Evans has published over 25 peer-reviewed articles, 10 abstracts, and is a co-inventor on 3 patents. Dr. Evans also is the principle investigator or co-investigator on four human trials focused on new strategies for imaging solid tumors. Dr. Evans serves on the scientific advisory board of ORIC Pharmaceuticals, Inc.

    Expertise:
    Cancer Biology, Molecular Imaging, and Organic Chemistry

    Specialty:
    Small molecule synthesis, proteomics, preclinical development of radiotracers, translation of human ready radiotracers, bioconjugation chemistry.

    Professional Interests:
    Cancer, molecular imaging of oncogene signaling with positron emission tomography, biomarkers, proteomics, organic chemistry, chemical biology, antibody development, prostate, brain, breast, oncogenes, androgen receptor, MYC, PI3K, tumor suppressors, signaling pathways, serum biomarkers, nuclear medicine

    Education and Training:
    • Bachelor of Art: St. Mary’s College, St. Mary’s City, Maryland - Chemistry
    • Doctor of Philosophy: The Scripps Research Institute, La Jolla, California - Organic Chemistry
    • Postdoctoral Fellowship: Memorial Sloan Kettering Cancer Center, New York - Molecular Imaging


    Collapse Research 
    Collapse Research Activities and Funding
    Development of a biomarker for imaging mTORC1 activity with PET
    American Cancer Society 130635-RSG-17-005-01-CCEJul 1, 2017 - Jun 30, 2021
    Role: PI
    Annotating MYC status in treatment resistant metastatic castration resistant prostate cancer with Gallium-68 citrate PET
    Department of Defense Prostate Cancer Research Program W81XWH-16-1-0469Aug 30, 2016 - Aug 31, 2019
    Role: Co-I
    Development of a radioligand to measure glucocorticoid receptor expression in enzalutamide resistant prostate cancer
    Department of Defense Prostate Cancer Research Program W81XWH-15-1-0552Sep 28, 2015 - Sep 29, 2017
    Role: PI
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH/NCI R00CA172695Jan 1, 2014 - Dec 31, 2016
    Role: Principal Investigator
    Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET
    NIH/NCI R01CA176671Apr 1, 2013 - Mar 31, 2018
    Role: Principal Investigator
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH/NCI K99CA172695Jan 3, 2013 - Dec 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials
    Collapse Featured Videos
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Aggarwal R, Behr S, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Premasekharan G, Huang J, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real time transferrin-based PET detects MYC-positive prostate cancer. Mol Cancer Res. 2017 Jun 07. PMID: 28592703.
      View in: PubMed
    2. Truillet C, Cunningham JT, Parker MF, Huynh LT, Conn CS, Ruggero D, Lewis JS, Evans MJ. Non-invasive measurement of mTORC1 signaling with 89Zr-transferrin. Clin Cancer Res. 2016 Dec 22. PMID: 28007777.
      View in: PubMed
    3. Hope TA, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience. J Nucl Med. 2016 Sep 22. PMID: 27660139.
      View in: PubMed
    4. Truillet C, Thomas E, Lux F, Huynh LT, Tillement O, Evans M, et al. Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles. Mol Pharm. 2016 Jul 5; 13(7):2596-601. PMID: 27266800.
      View in: PubMed
    5. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans M, et al. A Feasibility Study Showing [(68)Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 May 16. PMID: 27184068.
      View in: PubMed
    6. Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans M. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 Jun 17; 11(6):1587-94. PMID: 27008570.
      View in: PubMed
    7. Liu, W.; Truillet, C.; Flavell, R.R.; Brewer, T.; Evans, M.J.; Wilson, D.M.; Chang, C. A Reactivity-Based [18F]FDG Probe for In Vivo Formaldehyde Imaging Using Positron Emission Tomography. Chemical Science. 2016; (7):5503-5507.
    8. Carroll, V.N.; Truillet, C.; Shen, B.; Flavell, R.R.; Shao, X.; Evans, M.J.; VanBrocklin, H.F.; Scott, P.H.J.; Chin, F.T.; Wilson, D.M. 11C-Ascorbic and 11C-dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chemical Communications. 2016; 27(52):4888-4890.
    9. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans M. Applying (89)Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm. 2016 Feb 1; 13(2):683-8. PMID: 26725682.
      View in: PubMed
    10. Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8. PMID: 26649808.
      View in: PubMed
    11. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015 Nov 15; 75(22):4688-96. PMID: 26432404; PMCID: PMC4651750 [Available on 11/15/16].
    12. Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec; 68(6):1076-82. PMID: 25794458; PMCID: PMC4573834.
    13. Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. J Nucl Med. 2014 Dec; 55(12):2045-9. PMID: 25453051; PMCID: PMC4410715.
    14. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. PMID: 25128497; PMCID: PMC4197965.
    15. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):985-94. PMID: 24604591; PMCID: PMC4120276.
    16. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging. 2014; 13. PMID: 25248353; PMCID: PMC4545649.
    17. Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg Chem. 2014 Feb 17; 53(4):1880-99. PMID: 24313747; PMCID: PMC4151561.
    18. Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013 Nov; 54(11):1876-82. PMID: 24029655; PMCID: PMC4274751.
    19. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep; 110(3):484-92. PMID: 23903407; PMCID: PMC4029064.
    20. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013; 2:e00499. PMID: 23580326; PMCID: PMC3622181.
    21. Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging. 2013 Jan-Feb; 12(1):67-73. PMID: 23348793.
      View in: PubMed
    22. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med. 2013 Jan; 54(1):90-5. PMID: 23236019; PMCID: PMC3747823.
    23. Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012 Nov; 2(11):985-94. PMID: 23043150; PMCID: PMC3508522.
    24. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct; 18(10):1586-91. PMID: 23001181; PMCID: PMC3521603.
    25. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr; 2(4):320-7. PMID: 22576209; PMCID: PMC3351274.
    26. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012 Jul; 62(1):78-84. PMID: 22306323; PMCID: PMC3402084.
    27. Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med. 2012 Feb; 53(2):281-6. PMID: 22228793.
      View in: PubMed
    28. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011 Jun 7; 108(23):9578-82. PMID: 21606347; PMCID: PMC3111331.
    29. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 6; 107(14):6459-64. PMID: 20308550; PMCID: PMC2851999.
    30. Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst. 2007 Jul; 3(7):495-506. PMID: 17579775.
      View in: PubMed
    31. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 1; 445(7127):541-5. PMID: 17237762.
      View in: PubMed
    32. Evans MJ, Cravatt BF. Mechanism-based profiling of enzyme families. Chem Rev. 2006 Aug; 106(8):3279-301. PMID: 16895328.
      View in: PubMed
    33. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005 Oct; 23(10):1303-7. PMID: 16200062.
      View in: PubMed
    Michael's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP